Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,461.44 -7.86 (-0.14%) Dow
38,952.58 -159.58 (-0.41%) Nasdaq
17,740.14 +22.48 (+0.13%) Bitcoin USD
61,804.67 +734.66 (+1.20%) CMC Crypto 200
1,277.43 -6.36 (-0.50%)
ITCI Jan 2025 85.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:08PM EDT. Market open.
| Previous close | 4.6700 |
| Open | 4.6700 |
| Bid | 2.2500 |
| Ask | 5.4000 |
| Strike | 85.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.6700 - 4.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.